Lanean...

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide

Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Nephrol Renovasc Dis
Egile Nagusiak: Eidman, Keith E, Wetmore, James B
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5804266/
https://ncbi.nlm.nih.gov/pubmed/29440923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S128252
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!